- Home
- PDM vs PCRX Comparison
PDM vs PCRX Comparison
Compare PDM & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDM
- PCRX
- Stock Information
- Founded
- PDM 1997
- PCRX 2006
- Country
- PDM United States
- PCRX United States
- Employees
- PDM N/A
- PCRX N/A
- Industry
- PDM Building operators
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- PDM Real Estate
- PCRX Health Care
- Exchange
- PDM Nasdaq
- PCRX Nasdaq
- Market Cap
- PDM 1.1B
- PCRX 1.2B
- IPO Year
- PDM N/A
- PCRX 2011
- Fundamental
- Price
- PDM $8.82
- PCRX $26.79
- Analyst Decision
- PDM Buy
- PCRX Buy
- Analyst Count
- PDM 5
- PCRX 6
- Target Price
- PDM $9.40
- PCRX $30.00
- AVG Volume (30 Days)
- PDM 655.7K
- PCRX 592.7K
- Earning Date
- PDM 10-23-2025
- PCRX 11-05-2025
- Dividend Yield
- PDM 2.84%
- PCRX N/A
- EPS Growth
- PDM N/A
- PCRX N/A
- EPS
- PDM N/A
- PCRX N/A
- Revenue
- PDM $565,502,000.00
- PCRX $705,848,000.00
- Revenue This Year
- PDM $0.09
- PCRX $7.36
- Revenue Next Year
- PDM N/A
- PCRX $10.07
- P/E Ratio
- PDM N/A
- PCRX N/A
- Revenue Growth
- PDM N/A
- PCRX 2.25
- 52 Week Low
- PDM $5.46
- PCRX $13.04
- 52 Week High
- PDM $11.12
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- PDM 68.71
- PCRX 61.38
- Support Level
- PDM $8.53
- PCRX $26.22
- Resistance Level
- PDM $8.92
- PCRX $27.50
- Average True Range (ATR)
- PDM 0.19
- PCRX 0.92
- MACD
- PDM 0.01
- PCRX -0.07
- Stochastic Oscillator
- PDM 88.64
- PCRX 63.18
About PDM Piedmont Office Realty Trust Inc.
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across major U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.